1. |
Position statement on use of aspirin for MI prophylaxis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1194KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 3-3
&NA;,
Preview
|
PDF (1055KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1143KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1008KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
5. |
‘CholestaGel’ and lovastatin reduce LDL-cholesterol levels |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1119KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
6. |
New hormonal approaches for osteoporosis on the horizon |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 7-8
Larry Prescott,
Preview
|
PDF (2249KB)
|
|
摘要:
A number of studies involving the use of new non-estrogen hormones for the treatment of either postmenopausal or corticosteroid-induced osteoporosis demonstrate the promise of these agents as emerging therapeutic modalities. Results from some of these studies were presented at the 19th Annual Meeting of the American Society of Bone and Mineral Research [Cincinnati, US, September 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1189KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 9-9
&NA;,
Preview
|
PDF (1034KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
9. |
Rivastigmin beneficial in Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1117KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
10. |
Aromatase inhibitors: a niche in second-line breast cancer therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1107,
1997,
Page 11-12
Robert Carlson,
Preview
|
PDF (2214KB)
|
|
摘要:
The main treatment goal for postmenopausal women with advanced breast cancer who fail tamoxifen therapy is palliation, using further endocrine therapy to block tumour growth and reduce symptoms. Until recently, standard second-line therapy has been with a progestin (megestrol or medroxyprogesterone) or a non-specific aromatase inhibitor (aminoglutethimide). Two papers presented at the European Cancer Conference (ECCO) '97 [Hamburg, Germany; September 1997], and data discussed in symposia, showed that 2 of the newer aromatase inhibitors, letrozole [‘Femara’, Novartis] and anastrozole [‘Arimidex’, Zeneca], were superior in various comparisons to megestrol and that letrozole was superior to aminoglutethimide.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|